Skip to main content
Clinical Trials/NCT00842374
NCT00842374
Completed
Not Applicable

Single Center Registry of Non-STEMI Acute Coronary Syndrome Patients Treated With Bivalirudin

Minneapolis Heart Institute Foundation1 site in 1 country32 target enrollmentDecember 2008

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Non-STEMI Acute Coronary Syndrome
Sponsor
Minneapolis Heart Institute Foundation
Enrollment
32
Locations
1
Primary Endpoint
Incidence of MACE defined as any one of the following: • Acute myocardial infarction/reinfarction • Ischemia-driven unplanned revascularizations • Stroke • All cause Mortality
Status
Completed
Last Updated
13 years ago

Overview

Brief Summary

This is a registry of patients with non ST segment elevation Myocardial Infarction (heart attack) and/or unstable acute coronary artery syndrome treated with a standardized protocol including Bivalirudin.

Data will be collected on diagnosis, treatment and outcomes.

Registry
clinicaltrials.gov
Start Date
December 2008
End Date
December 2012
Last Updated
13 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Chest pain or symptoms believed to be an anginal equivalent and representing myocardial ischemia, lasting at least 10 minutes within the past 24 hours
  • Having any one of the following:
  • Ischemic changes on ECG: ST depression \>0.5 mm OR T wave inversion \>2 mm
  • Positive cardiac markers
  • New onset CHF presumed secondary to ischemia
  • Pulmonary edema
  • Known coronary artery disease with typical symptoms
  • Hemodynamic instability
  • Sustained ventricular tachycardia

Exclusion Criteria

  • For the purpose of the SSDI, patients will be excluded if we are unable to obtain their Social Security Number.

Outcomes

Primary Outcomes

Incidence of MACE defined as any one of the following: • Acute myocardial infarction/reinfarction • Ischemia-driven unplanned revascularizations • Stroke • All cause Mortality

Time Frame: 30 days

Secondary Outcomes

  • Rehospitalization for ACS(30 days)
  • Major Bleeding(in hospital and at 30 days)
  • All cause mortality(30 days, one year and up to 5 years)

Study Sites (1)

Loading locations...

Similar Trials